Weight Loss Pills: How They Work, Safety, and History

How Weight Loss Pills Have Changed — and What That Means for Safety

How Weight Loss Pills Have Changed — and What That Means for Safety
iStock
Though recent data show a decrease in the U.S. adult obesity rate — 37 percent in 2025 compared with a record high of 39.9 percent in 2022 — the need for obesity treatments is still high.

Many people can lose weight by exercising more, eating less, and adding more fruits and vegetables to their diet, but multiple factors in addition to lifestyle changes play a role in managing obesity.

“[Obesity] is a lifelong disease that requires lifelong intervention, and even when people make lifestyle changes, they still have to fight against weight gain,” says Timothy Garvey, MD, a professor in the department of nutrition sciences and the director of the Diabetes Research Center at the University of Alabama in Birmingham. “Medications can stop the processes that cause this weight gain.”

Weight loss medications on the market today are generally approved for adults with obesity who have a body mass index (BMI) of 30 or higher, and adults with a BMI of 27 or higher who have at least one weight-related health problem such as high blood pressure, sleep apnea, or type 2 diabetes.

Early Weight Loss Drugs

A study that collected prescription data from more than 2.2 million adults eligible for treatment with weight loss medications from 2009 to 2015 highlights that in the past, very few people who met the criteria above took drugs to lose weight.

Part of the problem came down to safety concerns, particularly because so many of the first drugs used for weight loss decades ago had potentially life-threatening side effects.

As far back as the 1940s, cocktails of appetite suppressants known as “rainbow pills” were heavily marketed to American women. The capsules often contained amphetamines, diuretics, laxatives, and thyroid hormones to maximize weight loss and were typically mixed with drugs like barbiturates to mask side effects.

After these drugs were linked to severe side effects and death in the 1960s, the U.S. Food and Drug Administration (FDA) pulled them from the market.

“None of these medications were tested in long-term trials prior to repurposing them for the treatment of obesity. This raises the risk that they will have side effects not recognized in short-term therapy,” says Frank Greenway, MD, the chief medical officer and a professor at the Pennington Biomedical Research Center at Louisiana State University in Baton Rouge.

In the 1990s, another untested weight loss cocktail nicknamed fen-phen took off. It contained the psychiatric drug fenfluramine, which boosts levels of

the brain chemical serotonin and induces feelings of satiety, with the appetite suppressant phentermine. Both drugs were recalled in 1997 due to concerns that they caused heart valve defects.

And in 2020, the FDA recalled prescription weight loss drug lorcaserin (Belviq) over cancer concerns after more than a decade on the market.

Tougher Drug Testing Requirements

After so many weight loss drugs were recalled because of dangerous side effects, the FDA has recommended that new medications to treat obesity undergo yearlong clinical trials before approval.

All the medications approved in the past decade have a good track record of safety so far, says Adam Gilden, MD, an associate professor and obesity medicine specialist at the University of Colorado School of Medicine in Aurora.

He says these newer drugs either combine medicines with good individual safety records or those that have been used for a long time to manage type 2 diabetes before gaining traction as obesity treatments.

“So, we can feel good that these medicines are safe,” Dr. Gilden adds. “Also, every one of these medicines will be subjected to large post-marketing trials, which will further assess safety and longer-term efficacy.”

“I think it is a very exciting time for obesity medicine because we now have several effective treatments to choose from,” says Melanie Jay, MD, an obesity researcher and a professor at the New York University Grossman School of Medicine in New York City.

Weight Loss Drug Options

For many people today, choosing a weight loss medication may come down to several factors, including what other medications they take, which drugs their insurance covers, affordability, and whether they prefer pills or injected medicines, Dr. Jay says.

“I advise people to speak to their physician to choose an initial medication and see how they respond,” says Jay. “It’s not uncommon to switch medications or have to add a second or third medication.”

Here’s what you need to know about currently approved prescription weight loss drugs.

Tirzepatide (Zepbound)

This weekly injected medicine was approved by the FDA in 2023 to treat adults with obesity and overweight adults with at least one weight-related chronic health problem.

How it works: Tirzepatide mimics two hormones that regulate insulin secretion and digestion: glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In the SURMOUNT-1 trial, participants using the highest dose lost an average of 22.5 percent of their body weight.

Common side effects: Nausea, diarrhea, vomiting, and constipation.

Interactions and risks: Rare but potentially dangerous reactions include severe gastrointestinal disease and acute injury to the pancreas, kidneys, or gallbladder.

Semaglutide (Wegovy)

Wegovy was approved by the FDA to treat adults with obesity as well as adults who are overweight and also have at least one weight-related chronic health problem.

The weekly injected form of the medicine was approved in 2021, and the once-daily oral version was approved in 2025.

How it works: It’s another GLP-1 receptor agonist that mimics a hormone in the brain that regulates appetite.

Common side effects: Nausea, diarrhea, vomiting, constipation, stomach pain, headache, and fatigue.

Interactions and risks: It can’t be used in combination with liraglutide or other GLP-1 receptor agonists that are prescribed for type 2 diabetes. Like other drugs in this family of medicines, including tirzepatide and liraglutide, it carries an increased risk of pancreatitis and has been linked to thyroid tumors in animals.

Orforglipron (Foundayo)

The FDA approved the oral drug Foundayo in 2026 for adults with obesity and adults who are overweight and have at least one co-occurring condition.

How it works: Orforglipron works like other GLP-1 receptor agonists, meaning it mimics a hormone that regulates appetite and fullness. But because it’s a small-molecule drug, it enters the bloodstream more easily and works when taken on a full stomach, unlike semaglutide.

Common side effects: This drug may cause abdominal pain, constipation, diarrhea, vomiting, nausea, headache, gas, bloating, and fatigue.

Interactions and risks: Rare adverse effects include gallbladder disease, kidney injury, retinal damage in people with type 2 diabetes, and pancreatitis. People using another GLP-1 receptor agonist shouldn’t use orforglipron. This medication has been linked to thyroid tumors in animal studies.

Naltrexone-Bupropion (Contrave)

This oral drug was approved by the FDA in 2014.

How it works: It’s a combination of two drugs that are used to treat addiction and depression, and it suppresses appetite and makes people feel full sooner.

Common side effects: Constipation, dizziness, diarrhea, dry mouth, headache, increased blood pressure, elevated heart rate, insomnia, liver damage, nausea, and vomiting.

Interactions and risks: People with uncontrolled blood pressure, seizures, a history of anorexia or bulimia, those taking psychiatric drugs containing bupropion (Wellbutrin, Zyban), or individuals dependent on opioids or in withdrawal from drugs or alcohol should avoid this medication. It can increase suicidal thoughts or actions.

Liraglutide (Saxenda)

The FDA approved this daily injected drug in 2014 for adults and in 2020 for children ages 12 and older with obesity.

How it works: It’s in a family of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking a hormone in the brain that regulates appetite and food consumption.

Common side effects: Nausea, diarrhea, constipation, vomiting, dizziness, hypoglycemia (low blood sugar), and increased heart rate. Rare side effects include an increased risk of pancreatitis, gallbladder disease, allergic reactions, and suicidal ideation. It’s also been linked to thyroid tumors in animals.

Interactions and risks: In a smaller dose, liraglutide is used as a diabetes medication called Victoza, which should not be used in conjunction with Saxenda.

Phentermine-Topiramate (Qsymia)

This pill was approved by the FDA in 2012 for adults who are overweight or obese, and in 2022 for patients ages 12 and older with obesity.

How it works: This combination pill suppresses appetite and makes people feel full sooner.

Common side effects: Constipation, dizziness, dry mouth, tingling in hands and feet, brain fog or cognitive impairment, depression, and difficulty sleeping.

Interactions and risks: People with closed angle glaucoma or hyperthyroidism, those who are pregnant or breastfeeding, and some individuals with a history of heart attack, stroke, heart rhythm disorders, kidney disease, or mood problems shouldn’t use it.

Orlistat (Xenical, Alli)

The FDA approved this pill in 1999 as a prescription weight loss drug (Xenical) and in 2007 at a lower dose for nonprescription use (Alli).

How it works: Orlistat works in the gut to limit the amount of fat you absorb from food.

Common side effects: Diarrhea, gas, stomach pain, and oily stool leakage.

Interactions and risks: It’s linked to rare cases of severe liver injury, dangerous interactions with cyclosporine (a drug to prevent organ transplant rejections), and the potential for malnutrition if patients don’t take a multivitamin.

Evidence suggests orlistat decreases the absorption of fat-soluble vitamins as well as some prescription medications, including Amiodarone (used to treat irregular heartbeats). It may also affect the dosage of warfarin, an anticoagulant.

People with malabsorption issues and those who are pregnant should avoid this medication.

What to Consider Before Taking Weight Loss Pills

It’s important to avoid weight loss medications during pregnancy or while trying to conceive.

People with kidney impairment and those at risk for kidney stones should discuss the risks and benefits of weight loss medication with a medical provider.

So should anyone with an eating disorder and those who are at risk.

The most recent guidelines on treating obesity also emphasize the importance of combining weight loss medications with lifestyle changes including healthy diet, physical activity, and regular wellness check-ins with an obesity specialist.

Resources We Trust

Adam Gilden, MD, MSCE

Medical Reviewer

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Me...

lisa-rapaport-bio

Lisa Rapaport

Author
Lisa Rapaport is a journalist with more than 20 years of experience on the health beat as a writer and editor. She holds a master’s degree from the UC Berkeley Graduate School of J...
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Witters D et al. Obesity Rate Declining in U.S. Gallup. October 28, 2025.
  2. Masood B et al. Causes of Obesity: A Review. Clinical Medicine. July 2023.
  3. Prescription Medications to Treat Overweight and Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. June 2024.
  4. Saxon DR et al. Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015. Obesity. December 2019.
  5. Bray GA et al. An Historical Review of Steps and Missteps in the Discovery of Anti-Obesity Drugs. Endotext. July 2022.
  6. FDA Requests the Withdrawal of the Weight-Loss Drug Belviq, Belviq XR (Lorcaserin) From the Market. U.S. Food and Drug Administration. February 13, 2020.
  7. Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction Guidance for Industry. U.S. Food and Drug Administration. January 2025.
  8. FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration. November 8, 2023.
  9. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. June 2022.
  10. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. U.S. Food and Drug Administration. March 8, 2024.
  11. Singh G et al. Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management. Journal of Investigative Medicine. October 2021.
  12. Novo Nordisk A/S: Wegovy Pill Approved in the U.S. as First Oral GLP-1 for Weight Management. Novo Norodisk. December 22, 2025.
  13. FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration. April 1, 2026.
  14. Approval Package for: Application Number: 200063Orig1s000. U.S. Food and Drug Administration. September 10, 2014.
  15. Chetty T. Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program. (COR-WM). ClinicalTrials.gov. August 2023.
  16. FAQs. Contrave.
  17. FDA Approves Weight Management Drug for Patients Aged 12 and Older. U.S. Food and Drug Administration. June 15, 2021.
  18. Saxenda (Liraglutide) Injection, for Subcutaneous Use. U.S. Food and Drug Administration. April 2023.
  19. FDA Approves Treatment for Chronic Weight Management in Pediatric Patients Aged 12 Years and Older. U.S. Food and Drug Administration. June 27, 2022.
  20. Orlistat (marketed as Alli and Xenical) Information. U.S. Food and Drug Administration (FDA). July 8, 2015.
  21. Bansal AB et al. Orlistat. StatPearls. February 2024.
  22. Munoz-Mantilla D. Top Weight Loss Medications. Obesity Medicine Association. April 2, 2026.
  23. Sauerwein K. Study Identifies Benefits, Risks Linked to Popular Weight-Loss Drugs. WashU Medicine. January 20, 2025.
  24. Santucci P. GLP-1 Medications & Eating Disorders. National Association of Anorexia Nervosa and Associated Disorders. April 3, 2025.
  25. WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity. World Health Organization. December 1, 2025.